Pyrimidine-2,4-dione derivatives as matrix metalloproteinase...

Details Pyrimidine-2,4-dione derivatives as matrix metalloproteinase... Pyrimidine-2,4-dione derivatives as matrix metalloproteinase...

2007-01-09

2007-01-09

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S299000, C544S300000, C544S309000, C544S310000

Reexamination Certificate

active

10634419

ABSTRACT:
This invention provides compounds defined by Formula Ior a pharmaceutically acceptable salt thereof,wherein R1, Q, R2, R3, and R4are as defined in the specification. The invention also provides related pharmaceutical compositions, methods of use, and combinations.

REFERENCES:
patent: 5130317 (1992-07-01), Baader et al.
patent: 5260323 (1993-11-01), Baader et al.
patent: 5519038 (1996-05-01), Baader et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6177437 (2001-01-01), Wright
patent: 6656932 (2003-12-01), Picard et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0087924 (2003-05-01), Sorenson
patent: 2003/0130278 (2003-07-01), Gaudilliere et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2003/0229103 (2003-12-01), Weithmann et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 2082076 (1993-05-01), None
patent: 284 226 (2000-11-01), None
patent: 0 420 763 (1991-04-01), None
patent: 0 935 963 (1999-08-01), None
patent: 1 069 110 (2001-01-01), None
patent: 1 138 680 (2001-10-01), None
patent: WO 00/09485 (2000-02-01), None
patent: WO-00/51990 (2000-09-01), None
patent: WO 01/12611 (2001-02-01), None
patent: WO 01/29010 (2001-04-01), None
patent: WO 01/63244 (2001-08-01), None
patent: WO 01/72718 (2001-10-01), None
patent: WO 02/34726 (2002-05-01), None
patent: WO 02/34753 (2002-05-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 02/064572 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064595 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO 03/032999 (2003-04-01), None
patent: WO 03/033478 (2003-04-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 04/000322 (2003-12-01), None
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,531, filed Aug. 5, 2003, Johnson.
U.S. Appl. No. 10/634,709, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,162, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,473, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,289, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,180, filed Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, filed Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, filed Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,288, filed Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,717, filed Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,177, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,290, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,182, filed Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,713, filed Aug. 5, 2003, Picard.
U.S. Appl. No. 10/634,225, filed Aug. 5, 2003, Picard et al.
U.S. Appl. No. 10/634,718, filed Aug. 5, 2003, Ortwine.
U.S. Appl. No. 10/739,261, filed Dec. 18, 2003, Bunker et al.
Office Action mailed Jun. 16, 2003, in U.S. Appl. No. 10/264,764.
International Search Report in PCT/IB03/03525.
Chen et al., “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy, and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, vol. 122, pp. 9648-9654.
Lovejoy et al., “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biology, vol. 6, No. 3, Mar. 1999, pp. 217-221.
Moy et al., “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000, vol. 302, pp. 671-689.
Mitchell et al., “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., vol. 97, No. 3, Feb. 1996, pp. 761-768.
Neuhold et al., “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice”, J. Clin. Invest., vol. 107, No. 1, Jan. 2001, pp. 35-44.
Dahlberg et al., “Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor That Spares Collagenase 1 (Matrix Metalloproteinase 1)”, Arthritis & Rheumatism, vol. 43, No. 3, Mar. 2000, pp. 673-682.
Billinghurst et al., “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthritis & Rheumatism, vol. 43, No. 3, Mar. 2000, pp. 664-672.
Billinghurst et al., “Enhanced Cleavage of Type II Collagen by Collagenases in Osteoarthritic Articular Cartilage”, J. Clin. Invest., vol. 99, No. 7, Apr. 1997, pp. 1534-1545.
Hirota et al., “Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyrido[2,3-d]-Pyrimidines and Quinazolines via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, vol. 37, No. 1, 1994, pp. 563-570.
Wernicke et al., “Cloning of Collagenase 3 from the Synovial Membrane and Its Expression in Rheumatoid Arthritis and Osteoarthritis”, The Journal of Rheumatology, vol. 23, No. 4, 1996, pp. 590-595.
Reboul et al., “The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J. Clin. Invest., vol. 97, No. 9, May 1996, pp. 2011-2019.
Freemont et al., “In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage”, Ann. Rheum. Dis., vol. 58, 1999, pp. 357-365.
Tarantino et al., “Inhibitors of DNA Polymerase III as Novel Antimicrobial Agents against Gram-Positive Eubacteria”, Antimicrobial Agents and Chemotherapy, vol. 43, No. 8, 1999, pp. 1982-1987.
Makino et al., Chemical Abstracts Service AN 1995:392279 for “Caplus Online”.
Fuchigami et al., Chemical Abstracts Service DN 106:18608 for “Caplus Online”.
Chem. Abst. Serv. Order No. AB-323/13887016 for “Chemcats Online”.

Affiliated with

Also associated with

Rating

Pyrimidine-2,4-dione derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidine-2,4-dione derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine-2,4-dione derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3785408